# Unimed Biotech Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/unimed-biotech-co

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.unimeddx.com
- Latest round: Series A (Dec 5, 2019)
- Investors on record: 1

## About

Based in Shanghai, China and established in 2013, Unimed Biotech Co. Ltd. is a biotechnology company that focuses on reproduction and genetics technology providing pre-pregnancy genetic testing and testing equipment. The company was founded by Shen Yang, who holds a Master's degree in Public Health Management from Yale University and has nearly 20 years of experience in the field of assisted reproduction. Shen has worked with domestic prenatal diagnosis centers and reproductive centers to build technical platforms. The core team of Unimed Biotech consists of top researchers, engineers, and operational staff from around the world, with 19 doctors and 20 masters among its members. The company has developed innovative technologies in the capture and separation of rare cells, chip technology, sequencing, and bioinformatics analysis.

Unimed Biotech offers a range of services and products in the reproductive and genetic sectors. The company's key offerings include pre-implantation genetic testing (PGT), prenatal screening, prenatal diagnosis, and its proprietary single-cell non-invasive prenatal gene testing technology known as cb-NIPT. The cb-NIPT technology allows for the detection of fetal cells in maternal blood for comprehensive genomic information, avoiding the influence of maternal genetic background. The company also provides a complete set of solutions for the challenges encountered in the process of creating a third-generation test-tube baby, including SNP chip platform construction and training for embryo biopsy and PGT chip experiments.

The company generates revenue by providing molecular diagnostic tests, genetic diagnosis for hereditary diseases, microbial identification, normal flora testing, and precision treatment for tumor individualization. It also offers professional medical testing and scientific research services.

The company secured an exclusive A-round investment which will be used for the construction of the company's clinical inspection center, completion of the single-cell capture system development, and advancement of clinical approvals for assisted reproductive projects.

## Funding rounds

- Series A, Dec 5, 2019 — China International Capital Corporation

## Investors

- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series A